FOXO4
Senolytic peptide that selectively induces apoptosis in senescent cells by disrupting FOXO4-p53 interaction.
Regulatory status (as of Sept 2026)
Not FDA-approved. Not among the peptides named in the 2026 PCAC actions.
See the FDA peptide regulatory tracker · Read our July 27, 2026 dispatch on the FDA PCAC peptide vote3 studies referenced · Last reviewed Oct 1, 2026 · Reviewed by The Peptide Dispatch Editorial Team · How we research & label content
FOXO4-DRI is a compound studied only in animals and lab experiments so far. Senolytic peptide that selectively induces apoptosis in senescent cells by disrupting FOXO4-p53 interaction.
| Half-life | Not established in published research |
|---|---|
| How it's given in studies | Subcutaneous injection |
| Research stage | Preclinical (animal) |
| Dosing | Published research: No published human dosing detailsFast-aging Xpd(TTD) mice and naturally aged mice, systemic (i.p.) dosing (Baar 2017). The exact mg/kg and schedule are in the full text. Also studied in senescent cell cultures. No human dosing is published.Community-reportedCommunity-reported: Research varies, subcutaneous injection |
Published-research dosing is what was given in the cited studies (species and units as reported). Community-reported dosing is what users describe, not from clinical studies. Neither is a recommendation. Not medical advice.
Where each point comes from: Clinicalhuman trials and FDA labels Lab / animalrodent, cell and ex vivo studies Community-reporteduser experience and commonly used protocols, not from clinical studies
In plain terms: It is designed to make worn-out (senescent) cells self-destruct; this was studied in mice and cells. Proposed mechanism, from mouse and cell studies: a D-retro-inverso peptide that interferes with FOXO4-p53 binding in senescent cells, triggering their apoptosis (Baar 2017). Structural NMR work maps the interaction to the p53 transactivation domain (Bourgeois 2025).
How to read this: Each item below is an effect observed in research subjects in the cited studies — think of Dexter, our stand-in research subject. These are findings from the literature, not results you should expect, and not medical advice.
Community-reportedIn user communities, reported doses vary widely (subcutaneous injection). This is not a recommendation.
Community reports are anecdotal, vary widely in product quality and purity, and are not medical advice. Talk to a licensed provider.
New research, FDA peptide updates, and what users are reporting. One email a week. Unsubscribe anytime.
| Peptide | Half-Life | Route | Research Status |
|---|---|---|---|
| FOXO4-DRI | Unknown | Subcutaneous injection | Preclinical (animal) |
| Epitalon | Unknown | Subcutaneous injection | Preclinical (animal) |
| GDF-11 | Unknown | Subcutaneous injection | Preclinical (animal) |
| Humanin | Unknown | Subcutaneous injection | Preclinical (animal) |
| Matrixyl (Palmitoyl Pentapeptide-4) | Topical (not systemically relevant) | Topical | Cosmetic/topical |
Values reflect figures reported in published research. Compare any peptides side-by-side →
This peptide belongs to the Anti-Aging category. View All Anti-Aging Peptides
From Our Affiliated Clinic
1836 Wellness is a physician-supervised clinic in Houston, TX. Discussing a compound on this page is not an offer to prescribe or supply it.
See how it works →Disclosure: The Peptide Dispatch and 1836 Wellness are commonly owned by 1836 Wellness LLC. We may benefit financially if you become a client of 1836 Wellness. Learn more.
Dosing, half-life figures, and mechanism descriptions on this page are compiled from peer-reviewed published research, with the species and study type stated where reported. Figures labeled “Dosing used in published research” describe what was given in those studies and do not constitute dosing recommendations for any human use. Each cited paper is listed with DOI and PubMed links in the References section above. Found an error? Contact us.